As wellness and longevity practices incorporate peptide services, legal risk often arises not from peptide use, but from who controls the medical decisions behind them. Because prescribing and administering peptides is considered the practice of medicine, offering these therapies triggers health care rules, primarily corporate practice of medicine (“CPOM”) considerations that directly affect ownership structures, management arrangements, and physician oversight. Thirty-three states have some version of CPOM. For medical spas and wellness centers, CPOM compliance is the first foundational requirement that any practice must understand when considering offering a peptide program.
Are Peptides Considered the Practice of Medicine?
Peptides exist as both over-the-counter (OTC) products and prescription medications, depending on their type and intended use. For example, those found in collagen supplements and skincare fall more within the OTC/wellness category. When used to diagnose, prevent, or treat disease or physical conditions, peptides are regulated as prescription drugs and must be ordered and overseen by appropriately licensed prescribing providers. As a result, decisions related to peptide selection, dosing, administration, and patient eligibility are medical decisions, not business ones.
This distinction is critical for CPOM purposes. Even when peptides are marketed as part of a wellness or longevity program, their use in patient care places them squarely within the practice of medicine. Practices in CPOM states thus cannot sidestep CPOM requirements by labeling peptide services as “wellness” offerings or lifestyle enhancements. Once peptides are recognized as medical services, the focus shifts to what health care laws regulate them and who may control those services.
Corporate Practice of Medicine Risks in Peptide Programs
CPOM laws are designed to ensure that medical judgment remains independent and is exercised solely by appropriately licensed medical professionals. While CPOM rules vary by state, they generally prohibit non-physicians and non-professional entities from owning medical practices and controlling medical decision-making.
In the context of peptides, CPOM concerns commonly arise when:
- A non-physician owns a practice where peptides are offered.
- A non-physician influences prescribing decisions, product sourcing, protocols, or patient eligibility.
- Management entities exert control over clinical operations rather than administrative functions.
Even well-intentioned involvement by business owners or management companies can cross CPOM lines if it affects how medical decisions are made. Because these risks often center on who holds decision-making authority, physician oversight becomes a critical compliance issue.
Physician Oversight Requirements for Peptide Programs
A compliant peptide program requires that appropriately licensed providers retain full authority over medical judgment. This includes determining whether a peptide is appropriate for a particular patient, whether use is on-label or off-label, and whether an experimental peptide may be offered under applicable law.
That authority must remain independent. Physicians cannot be pressured or influenced by non-clinical parties to prescribe peptides based on business objectives, marketing strategies, or patient demand. Practices that rely on a physician medical director should ensure the role is structured to support active participation in patient care and medical decisions. Regulators increasingly scrutinize arrangements where physician involvement exists in name only, particularly when medical judgment is disconnected from day-to-day operations. An absentee physician is a red flag for these regulators. Ensuring meaningful physician oversight often requires careful attention to the practice’s legal and operational structure.
Understanding CPOM Compliance
CPOM laws vary by state, so it’s critical to understand that a structure that works in one state may be noncompliant in another. However, there are fundamental principles for CPOM-compliant models, which include:
- Separate professional entities owned by licensed physicians.
- Management Services Organizations (known in the industry as MSOs) that provide non-clinical support.
- Carefully drafted management services agreements that preserve clinical independence.
- Clear delineation between medical decision-making and administrative functions.
These principles are especially important for peptide programs, where clinical discretion is central and regulatory risk increases when off-label or experimental therapies are involved.
Risks of Off-Label and Experimental Peptide Use
While CPOM applies to all medical services, peptide programs often involve off-label or emerging therapies. These uses demand heightened medical judgment and reinforce the need for independence from business influence.
Decisions about whether to offer a particular peptide, how it is sourced, and how it is administered must remain with the appropriately licensed provider. Allowing non-physicians to shape these decisions can expose both the medical professional and the business entity to enforcement actions, fines, and licensure consequences. As such, financial incentives cannot drive the use of off-label or experimental peptides.
What Practices Need to Know About Offering Peptides
Medical Judgment Must Remain Independent
Prescribing and administering peptides is the practice of medicine and must be controlled by appropriately licensed practitioners.
Business Influence Creates CPOM Risk
Non-physician ownership or involvement in peptide-related medical decisions can violate CPOM laws.
Structures Must Be Designed for State-By-State Compliance
Practices need compliant entities and agreements that preserve clinical independence, especially when involving multiple states.
ByrdAdatto Can Help You Navigate CPOM Compliance for Peptides
Peptides may offer valuable opportunities for wellness and longevity practices, but only when they are implemented within a compliant legal structure. CPOM issues are often overlooked until regulators raise concerns, at which point corrective action can be costly and disruptive.
Our legal team helps medical spas, wellness centers, and practices evaluate ownership, mitigate CPOM risk, and build compliant models for safe, sustainable peptide programs. Contact ByrdAdatto for guidance on setting up a peptide program that protects your team and supports your business.
